戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eving control of malignant pleural effusion (pleurodesis).
2 for chest tube insertion and talc for slurry pleurodesis.
3 ave a role in symptom control beyond that of pleurodesis.
4 ue diagnosis or to effect symptom control by pleurodesis.
5 tly (P =.044) more negative in patients with pleurodesis.
6 sant agent into the pleural space to achieve pleurodesis.
7 ower morbidity than do those who do not have pleurodesis.
8 nt small-bore-catheter thoracostomy and talc pleurodesis.
9 desis would influence the development of the pleurodesis.
10 n molecules that may play a critical role in pleurodesis.
11 ant candidates should minimize the extent of pleurodesis.
12 issue damage and inflammation caused by talc pleurodesis.
13 6 patients, of whom 175 (88 assigned to talc pleurodesis, 87 assigned to VAT-PP) had confirmed mesoth
14 ade conditional recommendations for offering pleurodesis after an initial pneumothorax rather than po
15 pared with the toxicity profiles of standard pleurodesis agents.
16 urodesis (on a scale of 0 to 4, where 0 = no pleurodesis and 4 = complete pleurodesis) with mean scor
17 lid and simple tool to determine spontaneous pleurodesis and remove a non-functioning IPC, which woul
18 pulmonary oedema, predicting success of talc pleurodesis, asthma exacerbations, detecting chest wall
19 ich valves, digital air-leak monitoring, and pleurodesis at first presentation might lead to an incre
20 significant difference between IPCs and talc pleurodesis at relieving patient-reported dyspnea.
21  with greater pleural fluid output, multiple pleurodesis attempts, longer ICD retention, and lower pH
22 edure until the first recurrence and against pleurodesis being used as a reason to exclude patients f
23 und in LOS, CTO5, CTO10, CTO20, and need for pleurodesis between patients in RV/LV, FO/FC, IF/EF, or
24 eural injection of TGF-beta(2) may produce a pleurodesis both safely and painlessly.
25 omly assigned (1:1) to either VAT-PP or talc pleurodesis by computer-generated random numbers, strati
26 [VAS] 4 times/d; superiority comparison) and pleurodesis efficacy at 3 months (failure defined as nee
27   NSAID use resulted in noninferior rates of pleurodesis efficacy at 3 months.
28     There is early evidence of LTA-T-induced pleurodesis efficacy, suggesting that this might be a vi
29 (NSAIDs) are avoided because they may reduce pleurodesis efficacy.
30 t failed to meet noninferiority criteria for pleurodesis efficacy.
31                                         Talc pleurodesis failure (24.7%) was associated with greater
32  24F chest tubes were associated with higher pleurodesis failure (30% vs 24%), failing to meet noninf
33                  Secondary outcomes included pleurodesis failure at 30 and 180 days; time to pleurode
34  in no significant difference in the rate of pleurodesis failure at 90 days.
35 is a potential predictive biomarker for talc pleurodesis failure despite inferiority to pleural acidi
36  progression but its role in predicting talc pleurodesis failure is unclear.
37                                              Pleurodesis failure occurred in 30 patients (20%) in the
38                              At 90 days, the pleurodesis failure rate was 36 of 161 patients (22%) in
39                      The primary outcome was pleurodesis failure up to 90 days after randomization.
40 sRAGE had the most predictive value for talc pleurodesis failure, followed by HMGB1 and MMP9.
41  Participants were monitored for 90-day post-pleurodesis failure, pleural interventions, and survival
42 iated with the underlying mechanism for talc pleurodesis failure.
43 urodesis failure at 30 and 180 days; time to pleurodesis failure; number of nights spent in the hospi
44  of TGF-beta2 would (1) produce an effective pleurodesis faster; (2) stimulate more collagen depositi
45 tion to the talc, and essentially prevents a pleurodesis from developing.
46 the VAT-PP group and 57% (46-66) in the talc pleurodesis group (hazard ratio 1.04 [95% CI 0.76-1.42];
47                                              Pleurodesis had no statistically significant effect on t
48 s painful than larger tubes, but efficacy in pleurodesis has not been proven.
49 ents with mesothelioma who have talc-induced pleurodesis have a lower morbidity than do those who do
50  clinical trial among 320 patients requiring pleurodesis in 16 UK hospitals from 2007 to 2013.
51 ntrapleural injection of TGF-beta(2) induces pleurodesis in a dose-dependent manner.
52   A dose of 5.0 microg produced satisfactory pleurodesis in almost all of the rabbits so treated.
53 erall survival, and cost, of VAT-PP and talc pleurodesis in patients with malignant pleural mesotheli
54         The ability of TGF-beta to produce a pleurodesis in patients with recurrent pleural effusions
55 ministration of TGF-beta2 produced excellent pleurodesis in rabbits at a rate faster than talc slurry
56 has recently been shown to produce effective pleurodesis in rabbits.
57 factor beta(2) (TGF-beta(2)) would produce a pleurodesis in rabbits.
58                                              Pleurodesis influences the relationship between CT measu
59                                         Talc pleurodesis is a common and effective treatment.
60            Pleural abrasion with minocycline pleurodesis is as effective as apical pleurectomy and ei
61 5, CTO10, and CTO20, respectively), need for pleurodesis, length of hospital stay (LOS), operation du
62  66 [IQR 53-74 years]) with MPE who received pleurodesis, lung adenocarcinoma was the most common.
63 f corticosteroids at the time of talc-slurry pleurodesis markedly decreases the inflammatory reaction
64  to malignant pleural mesothelioma, and talc pleurodesis might be preferable considering the fewer co
65 tly more common after VAT-PP than after talc pleurodesis, occurring in 24 (31%) of 78 patients who co
66 ulmonary function tests and the influence of pleurodesis on these findings were assessed with regress
67  of TGF-beta(2) resulted in a dose-dependent pleurodesis (on a scale of 0 to 4, where 0 = no pleurode
68 is, follow up after thoracentesis, and offer pleurodesis or a drainage procedure for patients with re
69 ith 3 days (2-5) for those who received talc pleurodesis (p<0.0001).
70 ged LOS, greater chest tube output, and more pleurodesis (P<0.05), and PAP was related to CTO5 and CT
71  ten (14%) of 73 patients who completed talc pleurodesis (p=0.019), as were respiratory complications
72 ivariate analysis, performance of a chemical pleurodesis procedure and prolonged cardiopulmonary bypa
73                    The optimal thoracoscopic pleurodesis procedure for PSP with high recurrence risk
74 and show a four-fold increase when a similar pleurodesis procedure is done with a video-assisted appr
75 the risk of infection, and may necessitate a pleurodesis procedure.
76 ced effective pleurodesis within 7 d (median pleurodesis score = 7 at Day 7).
77 all 10 rabbits that received talc only had a pleurodesis score of 3 or 4, whereas only four of the 10
78 10 rabbits that also received steroids had a pleurodesis score of 3 or 4.
79 h malignant pleural effusion and no previous pleurodesis, there was no significant difference between
80                 In studies that did the same pleurodesis through two different forms of access, the r
81 al effusions (MPE) are treated with chemical pleurodesis to prevent recurrence.
82      Thirty-seven patients with LAM (17 with pleurodesis) underwent CT and pulmonary function tests.
83                                        Gross pleurodesis was graded from 1 (none) to 8 (complete symp
84    Small-bore-catheter thoracostomy and talc pleurodesis was successful in treating malignant pleural
85 ing growth factor beta (TGF-beta) to produce pleurodesis, we observed that although TGF-beta was more
86 tive protein from baseline to 48 hours after pleurodesis were recorded.
87 al effusion who had not previously undergone pleurodesis were recruited from 143 patients who were tr
88 We report two trials describing whether talc pleurodesis with a mean particle size of less than 15 mi
89                                              Pleurodesis with talc is an accepted method for the trea
90 4, where 0 = no pleurodesis and 4 = complete pleurodesis) with mean scores of 3.6, 2.6, 1.5, 0.7, and
91 al injection of TGF-beta2 produced effective pleurodesis within 7 d (median pleurodesis score = 7 at
92 t use of steroids at the time of talc-slurry pleurodesis would influence the development of the pleur
93 lude that the routine use of graded talc for pleurodesis would reduce the morbidity of this procedure